NCT07225946From ClinicalTrials.govRecruiting

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-engaging Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

At a glance

Phase: Phase 3
Study type: Interventional
Sponsor: Janssen Research & Development, LLC
Enrolment target: 800
Started: 19 December 2025
Main results due: 19 November 2027
Study sites: 158
Registry updated: 25 September 2026

Can you take part?

Aged 18 years and over.
Open to any sex.
You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria

Inclusion criteria:

* Have histologically confirmed adenocarcinoma of the prostate
* Have disease that is metastatic at the time of screening by computed tomography (CT) or magnetic resonance imaging (MRI) and 99m\^Tc bone scan as determined by the investigator
* Participants must receive ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) analog throughout the treatment or have had prior bilateral orchiectomy, and have serum testosterone less than or equal to (\<=) 50 nanogram per deciliter (ng/dL) (\<= 1.73 nanomoles per Liter \[nmol/L\]) at screening
* Have progressed by PSA or CT/MRI or 99m\^Tc bone scan on at least 1 novel androgen receptor pathway inhibition (ARPI) but no more than 2 different ARPI for any stage of disease. Must have discontinued ARPI before randomization into the study
* Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1

Exclusion criteria:

* Known history of either brain or leptomeningeal prostate cancer metastases
* Participants with known breast cancer gene 1/2 (BRCA 1/2) mutations (germline or somatic) who have not received treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor, unless not available or contraindicated
* Prior or concurrent second malignancy (other than the disease under study)
* Received cytotoxic chemotherapy for prostate cancer in any setting
* Received prior treatment with human kallikrein 2 (KLK-2) directed therapies

What this study is about

In the sponsor’s own words, from the registry.

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).

Study sites(158)

Arizona Clinical Trials
Chandler, Arizona, United States
Recruiting
Arkansas Urology
Little Rock, Arkansas, United States
Recruiting
MemorialCare Orange Coast Medical Center
Fountain Valley, California, United States
Recruiting
University Of California San Diego
La Jolla, California, United States
Recruiting
Cancer and Blood Specialty Clinic
Los Alamitos, California, United States
Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
Recruiting
Valkyrie Clinical Trials
Los Angeles, California, United States
Recruiting
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States
Recruiting
Kaiser Permanente Southern California
Riverside, California, United States
Recruiting
Sharp Center for Research
San Diego, California, United States
Recruiting
Providence Saint John s Health Center
Santa Monica, California, United States
Recruiting
Rocky Mountain Cancer Centers
Aurora, Colorado, United States
Recruiting
AdventHealth Porter Oncology Research
Denver, Colorado, United States
Recruiting
Vail Health Shaw Cancer Center
Edwards, Colorado, United States
Recruiting
Grand Valley Oncology
Grand Junction, Colorado, United States
Recruiting
Colorado Clinical Research
Lakewood, Colorado, United States
Recruiting
AdventHealth Orlando
Orlando, Florida, United States
Recruiting
Florida Cancer Specialists
Sarasota, Florida, United States
Recruiting
Winship Cancer Institute Emory University
Atlanta, Georgia, United States
Recruiting
Duly Health and Care
Lisle, Illinois, United States
Recruiting
Cancer Center of Kansas Heritage Plaza Medical Building
Wichita, Kansas, United States
Recruiting
St Elizabeth Healthcare
Edgewood, Kentucky, United States
Recruiting
Norton Cancer Institute
Louisville, Kentucky, United States
Recruiting
East Jefferson General Hospital
Metairie, Louisiana, United States
Recruiting
University of Maryland
Baltimore, Maryland, United States
Recruiting
Johns Hopkins Hospital
Baltimore, Maryland, United States
Recruiting
Johns Hopkins Medical Institutions
Baltimore, Maryland, United States
Recruiting
Chesapeake Urology Research Associates
Towson, Maryland, United States
Recruiting
Massachusetts General
Boston, Massachusetts, United States
Recruiting
Profound Research LLC at Cancer and Leukemia Center
Sterling Heights, Michigan, United States
Recruiting
HealthPartners Frauenshuh Cancer Center CRC West
Saint Louis Park, Minnesota, United States
Recruiting
HealthPartners Cancer Center at Regions Hospital CRC East
Saint Paul, Minnesota, United States
Recruiting
University of Mississippi Medical Center
Jackson, Mississippi, United States
Recruiting
Washington University
St Louis, Missouri, United States
Recruiting
NHO Revive Research Institute, LLC
Lincoln, Nebraska, United States
Recruiting
Astera Cancer Care
East Brunswick, New Jersey, United States
Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island
Mineola, New York, United States
Recruiting
NYU Langone Health Laura and Isaac Perlmutter Cancer Center
New York, New York, United States
Recruiting
Montefiore Medical Center
The Bronx, New York, United States
Recruiting
Duke University Medical Center
Durham, North Carolina, United States
Recruiting
University of Cincinnati
Cincinnati, Ohio, United States
Recruiting
Oregon Urology Institute
Springfield, Oregon, United States
Recruiting
Lehigh Valley Hospital
Allentown, Pennsylvania, United States
Recruiting
MidLantic Urology
Bala-Cynwyd, Pennsylvania, United States
Recruiting
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
Recruiting
University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Recruiting
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States
Recruiting
Avera Medical Group
Sioux Falls, South Dakota, United States
Recruiting
Prairie Lakes Health Care System
Watertown, South Dakota, United States
Recruiting
Tennessee Cancer Specialists
Knoxville, Tennessee, United States
Recruiting
Texas Oncology
Austin, Texas, United States
Recruiting
UT Southwestern Medical Center
Dallas, Texas, United States
Recruiting
Houston Metro Urology
Houston, Texas, United States
Recruiting
Texas Oncology 1
Sugar Land, Texas, United States
Recruiting
Renovatio Clinical
The Woodlands, Texas, United States
Recruiting
Virginia Cancer Specialists
Fairfax, Virginia, United States
Recruiting
Fred Hutch Cancer Center Sloan Clinic 2
Seattle, Washington, United States
Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Recruiting
Warringal Private Hospital
Heidelberg, Australia
Recruiting

Showing 60 of 158 sites — filter to narrow it down. 158 of the 158 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT07225946. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me